Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway

International Journal of Oncology

Volumn 47, Issue 4, 2015, Pages 1494-1502

  Huang, Haizhi ^a,f   Chen, Allen Y ^c   Ye, Xingqian ^b   Li, Bingyun ^d   Rojanasakul, Yon ^c   Rankin, Gary O ^e   Chen, Yi Charlie ^a  

^a Alderson Broaddus College   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Zhejiang Fangyuan Test Group   (China)

Author keywords

Apoptosis; Bax; Bcl xl; Ovarian cancer; P53

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; CISPLATIN; MYRICETIN; PROTEIN P53; ANTINEOPLASTIC AGENT; FLAVONOID; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940972145     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3133     Document Type: Article

References (37)

1. Stordal B and Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life 59: 696-699, 2007.
2. Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med 100: 704-713, 1984.
3. Milosavljevic N, Duranton C, Djerbi N, Puech PH, Gounon P, Lagadic-Gossmann D, Dimanche-Boitrel MT, Rauch C, Tauc M, Counillon L, et al: Nongenomic effects of cisplatin: Acute inhibition of mechanosensitive transporters and channels without actin remodeling. Cancer Res 70: 7514-7522, 2010.
4. Windsor RE, Strauss SJ, Kallis C, Wood NE and Whelan JS: Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer 118: 1856-1867, 2012.
5. Levi JA, Aroney RS and Dalley DN: Haemolytic anaemia after cisplatin treatment. Br Med J (Clin Res Ed) 282: 2003-2004, 1981.
6. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008.
7. Champeris Tsaniras S, Kanellakis N, Symeonidou IE, Nikolopoulou P, Lygerou Z and Taraviras S: Licensing of DNA replication, cancer, pluripotency and differentiation: An interlinked world? Semin Cell Dev Biol 30: 174-180, 2014.
8. Buolamwini JK: Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
9. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A and Cascante M: Targeting cell cycle regulation in cancer therapy. Pharmacol Ther 138: 255-271, 2013.
10. Brunelle JK and Letai A: Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci 122: 437-441, 2009.
11. Gates MA, Vitonis AF, Tworoger SS, Rosner B, Titus-Ernstoff L, Hankinson SE and Cramer DW: Flavonoid intake and ovarian cancer risk in a population-based case-control study. Int J Cancer 124: 1918-1925, 2009.
12. Ong KC and Khoo HE: Biological effects of myricetin. Gen Pharmacol 29: 121-126, 1997.
13. Ross JA and Kasum CM: Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr 22: 19-34, 2002.
14. Basli A, Soulet S, Chaher N, Mérillon JM, Chibane M, Monti JP and Richard T: Wine polyphenols: Potential agents in neuroprotection. Oxid Med Cell Longev 2012: 805762, 2012.
15. Z hang XH, Chen SY, Tang L, Shen YZ, Luo L, Xu CW, Liu Q and Li D: Myricetin induces apoptosis in HepG2 cells through Akt/p70S6K/bad signaling and mitochondrial apoptotic pathway. Anticancer Agents Med Chem 13: 1575-1581, 2013.
16. Phillips PA, Sangwan V, Borja-Cacho D, Dudeja V, Vickers SM and Saluja AK: Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Cancer Lett 308: 181-188, 2011.
17. Z ang W, Wang T, Wang Y, Li M, Xuan X, Ma Y, Du Y, Liu K, Dong Z and Zhao G: Myricetin exerts anti-proliferative, antiinvasive, and pro-apoptotic effects on esophageal carcinoma EC9706 and KYSE30 cells via RSK2. Tumour Biol 35: 12583-12592, 2014.
18. K im ME, Ha TK, Yoon JH and Lee JS: Myricetin induces cell death of human colon cancer cells via BAX/BCL2-dependent pathway. Anticancer Res 34: 701-706, 2014.
19. Li B, Gao Y, Rankin GO, Rojanasakul Y, Cutler SJ, Tu Y and Chen YC: Chaetoglobosin K induces apoptosis and G2 cell cycle arrest through p53-dependent pathway in cisplatinresistant ovarian cancer cells. Cancer Lett 356: 418-433, 2015.
20. Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T and Farley JH; Gynecologic Oncology Group: Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol 111: 487-495, 2008.
21. Yang YI, Kim JH, Lee KT and Choi JH: Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Gynecol Oncol 123: 588-596, 2011.
22. Wilson TR, Johnston PG and Longley DB: Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9: 307-319, 2009.
23. Liu T, Hannafon B, Gill L, Kelly W and Benbrook D: Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther 6: 1814-1822, 2007.
24. Ozören N and El-Deiry WS: Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13: 135-147, 2003.
25. Maggioni D, Nicolini G, Rigolio R, Biffi L, Pignataro L, Gaini R and Garavello W: Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro. Nutr Cancer 66: 1257-1267, 2014.
26. Shiomi K, Kuriyama I, Yoshida H and Mizushina Y: Inhibitory effects of myricetin on mammalian DNA polymerase, topoisomerase and human cancer cell proliferation. Food Chem 139: 910-918, 2013.
27. K ong D, Ma S, Liang B, Yi H, Zhao Y, Xin R, Cui L, Jia L, Liu X and Liu X: The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Biomed Pharmacother 66: 271-278, 2012.
28. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
29. K uo YC, Kuo PL, Hsu YL, Cho CY and Lin CC: Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 78: 2550-2557, 2006.
30. Basu A and Haldar S: The relationship between BcI2, Bax and p53: Consequences for cell cycle progression and cell death. Mol Hum Reprod 4: 1099-1109, 1998.
31. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590, 2003.
32. Guan YQ, Li Z, Yang A, Huang Z, Zheng Z, Zhang L, Li L and Liu JM: Cell cycle arrest and apoptosis of OVCAR-3 and MCF-7 cells induced by co-immobilized TNF-α plus IFN-γ on polystyrene and the role of p53 activation. Biomaterials 33: 6162-6171, 2012.
33. Ho JS, Ma W, Mao DY and Benchimol S: p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 25: 7423-7431, 2005.
34. Hermeking H and Eick D: Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091-2093, 1994.
35. Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980-3985, 2005.
36. Z hang XH, Zou ZQ , Xu CW, Shen YZ and Li D: Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Rep 4: 273-277, 2011.
37. Piccolo MT and Crispi S: The dual role played by p21 may influence the apoptotic or anti-apoptotic fate in cancer. J Cancer Res Updates 1: 189-202, 2012.